• Je něco špatně v tomto záznamu ?

Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset

C. Cooray, M. Mazya, R. Mikulik, L. Jurak, M. Brozman, P. Ringleb, A. Dixit, D. Toni, N. Ahmed,

. 2019 ; 50 (5) : 1149-1155. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006488

Background and Purpose- There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. Methods- We analyzed 109 291patients treated with intravenous thrombolysis, recorded in the Safe Implementation of Treatments in Stroke International Thrombolysis Register between 2003 and 2017 not taking oral anticoagulants or therapeutic doses of heparin at stroke onset. One thousand four hundred eleven patients (1.3%) were on prophylactic LMWH for deep venous thrombosis prevention. Outcome measures were symptomatic intracerebral hemorrhage, parenchymal hematoma, death within 7 days and 3 months, and functional dependency at 3 months. Results- Patients on LMWH were older, had more severe strokes, more prestroke disability, and comorbidities than patients without LMWH. There was no significant increase in adjusted odds ratios (aOR) for symptomatic intracerebral hemorrhage (aOR, 1.02 [95% CI, 0.48-2.17] as per Safe Implementation of Treatments in Stroke -MOST, aOR, 0.95 [0.59-1.53] per ECASS II]), nor for 7-day mortality (aOR, 1.14 [0.82-1.59]), in the prophylactic LMWH group. The LMWH group had a higher aOR for 3-month mortality (aOR, 1.94 [1.49-2.53]) and functional dependency, aOR, 1.44 (1.10-1.90). Propensity score analysis matching patients on baseline characteristics removed differences between groups on all outcomes except 3-month mortality. Conclusions- Intravenous thrombolysis in patients with acute ischemic stroke on treatment with prophylactic doses of LMWH at stroke onset is not associated with an increased risk of symptomatic intracerebral hemorrhage or early death.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006488
003      
CZ-PrNML
005      
20220103082720.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/STROKEAHA.118.024575 $2 doi
035    __
$a (PubMed)30943884
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cooray, Charith $u From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.A.).
245    10
$a Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset / $c C. Cooray, M. Mazya, R. Mikulik, L. Jurak, M. Brozman, P. Ringleb, A. Dixit, D. Toni, N. Ahmed,
520    9_
$a Background and Purpose- There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. Methods- We analyzed 109 291patients treated with intravenous thrombolysis, recorded in the Safe Implementation of Treatments in Stroke International Thrombolysis Register between 2003 and 2017 not taking oral anticoagulants or therapeutic doses of heparin at stroke onset. One thousand four hundred eleven patients (1.3%) were on prophylactic LMWH for deep venous thrombosis prevention. Outcome measures were symptomatic intracerebral hemorrhage, parenchymal hematoma, death within 7 days and 3 months, and functional dependency at 3 months. Results- Patients on LMWH were older, had more severe strokes, more prestroke disability, and comorbidities than patients without LMWH. There was no significant increase in adjusted odds ratios (aOR) for symptomatic intracerebral hemorrhage (aOR, 1.02 [95% CI, 0.48-2.17] as per Safe Implementation of Treatments in Stroke -MOST, aOR, 0.95 [0.59-1.53] per ECASS II]), nor for 7-day mortality (aOR, 1.14 [0.82-1.59]), in the prophylactic LMWH group. The LMWH group had a higher aOR for 3-month mortality (aOR, 1.94 [1.49-2.53]) and functional dependency, aOR, 1.44 (1.10-1.90). Propensity score analysis matching patients on baseline characteristics removed differences between groups on all outcomes except 3-month mortality. Conclusions- Intravenous thrombolysis in patients with acute ischemic stroke on treatment with prophylactic doses of LMWH at stroke onset is not associated with an increased risk of symptomatic intracerebral hemorrhage or early death.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x aplikace a dávkování $7 D000925
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a heparin nízkomolekulární $x aplikace a dávkování $7 D006495
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a preexpoziční profylaxe $x metody $7 D065129
650    _2
$a cévní mozková příhoda $x diagnóza $x farmakoterapie $x mortalita $7 D020521
650    _2
$a trombolytická terapie $x metody $x mortalita $x trendy $7 D015912
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mazya, Michael $u From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.A.).
700    1_
$a Mikulik, Robert $u International Clinical Research Center and Neurology Department, St Anne's University Hospital in Brno, Masaryk University, Czech Republic (R.M.).
700    1_
$a Jurák, Lubomír $u Neurocentre, Regional Hospital Liberec, Czech Republic (L.J.). $7 xx0267976
700    1_
$a Brozman, Miroslav $u Faculty Hospital Nitra, Constantine Philosopher University, Slovakia (M.B.).
700    1_
$a Ringleb, Peter $u Department of Neurology, Heidelberg University Hospital, Germany (P.R.).
700    1_
$a Dixit, Anand $u University of Newcastle upon Tyne and Newcastle upon Tyne Hospitals NHS Foundation Trust (A.D.).
700    1_
$a Toni, Danilo $u Emergency Department Stroke Unit, Hospital Policlinico Umberto I, Department of Neurology and Psychiatry, Sapienza University, Rome, Italy (D.T.).
700    1_
$a Ahmed, Niaz $u From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.A.).
773    0_
$w MED00010659 $t Stroke $x 1524-4628 $g Roč. 50, č. 5 (2019), s. 1149-1155
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30943884 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20220103082719 $b ABA008
999    __
$a ok $b bmc $g 1525346 $s 1096544
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 50 $c 5 $d 1149-1155 $e - $i 1524-4628 $m Stroke $n Stroke $x MED00010659
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...